Myeloproliferative Neoplasms

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.

Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.

A specialist in hematologic malignancies provides an overview of the JAK2 pathway as it relates to myeloproliferative neoplasms such as polycythemia vera.

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.

A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.

An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.

Catriona Jamieson, MD, PhD, discusses symptom management in patients with myelofibrosis.

Jean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.